Suchergebnisse - "Renaudineau, Yves"

PubPharm (306)

1

Blocking Orai1 constitutive activity inhibits B-cell cancer migration and synergistically acts with drugs to reduce B-CLL cell survival

enthalten in: European journal of pharmacology | 2024

von Scaviner, J. | Bagacean, C. | Christian, B. | +3

2

Type I interferon associated epistasis may contribute to early disease-onset and high disease activity in juvenile-onset lupus

enthalten in: Clinical immunology (Orlando, Fla.) | 2024

von Renaudineau, Y. | Charras, A. | Natoli, V. | +5

3

USE OF AN ANNELID MOLECULE FOR TREATING AND/OR PREVENTING AT LEAST ONE COMPLEMENT-ACTIVATION ASSOCIATED DISEASE

enthalten in: Europäisches Patentamt | 2024

von ZAL FRANCK | RENAUDINEAU YVES | PUISSANT-LUBRANO BÉNÉDICTE

4

Orai1 Ca2+ channel modulators as therapeutic tools for treating cancer : Emerging evidence!

enthalten in: Biochemical pharmacology | 2024

von Mignen, O. | Vannier, J. | Schneider, P. | +2

5

Impact of imlifidase treatment on immunoglobulins in an HLA-hypersensitized lupus nephritis patient with anti-SSA/SSB antibodies after kidney transplantation : A case report

enthalten in: Journal of translational autoimmunity | 2023

von Milhès, J. | Marion, O. | Puissant, B. | +6

6

Low performance of interferon gamma release assay Quantiferon-TB gold coupled or not with Pst1/3/lipoglycan humoral detection to predict Mycobacterium tuberculosis complex disease in a low-burden area

enthalten in: Tuberculosis (Edinburgh, Scotland) | 2023

von Martinez-Rivera, S. | Guet-Revillet, H. | Herin, F. | +5

7

Blocking Orai1 constitutive activity inhibits B-cell cancer migration and synergistically acts with drugs to reduce B-CLL cell survival

enthalten in: bioRxiv.org | 2023

von Scaviner, J. | Bagacean, C. | Christian, B. | +3

8

Lupus Nephritis Risk Factors and Biomarkers : An Update

enthalten in: International journal of molecular sciences | 2023

von Renaudineau, Y. | Brooks, W. | Belliere, J.

9

Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases

enthalten in: International immunopharmacology | 2023

von Boumaza, X. | Lafaurie, M. | Treiner, E. | +13

10

JAK inhibition for CD3- CD4+ lymphocytic-variant hypereosinophilic syndrome

enthalten in: Clinical immunology (Orlando, Fla.) | 2023

von Faguer, S. | Groh, M. | Vergez, F. | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[31]